We studied the effect of a novel a-amino-3hydroxy-5-methylisoxazole-4-propionic acid (AMPA)I kainate antagonist, YM90K [6-(IH-imidazol-1-yl)-7-nitro-2, 3(1H, 4H)-quinoxalinedione monohydrochloride], in a focal cerebral ischemia model using anesthetized cats. Cats were subjected to permanent occlusion of the middle cerebral artery (MCA) for 6 h, then killed and examined histologically. The amount of ischemic damage was as sessed in 12 stereotaxic coronal sections. Treatment with YM90K (i. v. infusion of 0.5 mg/5 mllkg/h) starting JO min after MCA occlusion markedly reduced the volume of ischemic damage (from 2823 ± 164 mm' of the cerebral
hemisphere in saline-treated cats to 1737 ± 305 mm' in YM90K-treated cats). No essential differences were ob served between YM90K-and saline-treated cats concern ing physiological variables or brain temperature. These results further support the notion that the AMPA/kainate receptor plays an important role in the pathogenesis of focal cerebral ischemia. This evidence for the neuropro tective efficacy ofYM90K in a gyrencephalic species sug gests its therapeutic potential in the treatment of human stroke. Key Words: AMPA/kainate antagonist-Focal ce rebral ischemia-Cat. cerebral ischemia (Wieloch et aI., 1985; Onodera et aI., 1986; Jprgensen et aI., 1986) . Glutamate acts on two distinct subtypes of postsynaptic ionotropic re ceptors, namely, the N-methyl-o-aspartate (NMDA) and ex-amino-3-hydroxy-5-methylisox azole-4-propionic acid (AMPA)/kainate (or non NMDA) subtypes (Watkins et aI., 1990) . Of these two subtypes, the NMDA receptor was first postu lated to mediate glutamate neurotoxicity since the ion channel of this subtype is highly permeable to Ca 2+ (MacDermott et aI., 1986; Uematsu et aI., 1989a) . In fact, neuroprotective effects of NMDA antagonists have been demonstrated in models of focal cerebral ischemia (Park et aI., 1988a, b; Bul lock et aI., 1990; Gill et aI., 1991; Uematsu et aI., 1991) , although their neuroprotective effects in global cerebral ischemia have been controversial (Fleischer et aI., 1989; Michenfelder et aI., 1989; Sterz et aI., 1989; Lanier et aI., 1990; Buchan et aI., 1991b; Nellgard et aI., 1991; Nellgard and Wieloch, 1992) . However, accumulating evidence suggests that the AMPA/kainate receptor is also involved in neuronal damage following cerebral ischemia.
AMPA/kainate antagonists, such as 2,3-dihydroxy-6-nitro-7 -sulfamoyl-benzo(F)quinoxaline (NBQX) and GYKI 52466 [1-(4-aminophenyl)-4-methyl-7 ,8methylene-dioxy-5H-2,3-benzodiazepine hydro chloride], have shown neuroprotective effects in both transient global (Sheardown et a!. , 1990 (Sheardown et a!. , , 1993 Buchan et a!., 1991a; Diemer et a!. , 1992; Le Peillet et a!. , 1992; Nellgard and Wieloch 1992; Li and Buchan, 1993) and focal cerebral ischemia models in rodents (Xue et a!., 1994; Gill et a!. , 1992; Smith and Meldrum, 1992) . Another AMPA/kainate antag onist, LY-293558, has been proven effective in re ducing neuronal damage in a cat focal cerebral isch emia model (Bullock et al,. 1994 ).
We have recently developed a novel and potent AMPA/kainate antagonist, YM90K [6-(1H-imid azol-1-yl)-7-nitro-2, 3(1H, 4H)-quinoxalinedione monohydrochloride] (Ohmori et a!. , 1994) , and re ported that it possesses more potent neuroprotec tive effect than does NBQX in a gerbil global cere bral ischemia model (Shimizu-Sasamata et a!. , 1996) . In this model, YM90K was effective even when administered 6 h after induction of ischemia.
This agent also has a neuroprotective effect against neuronal damage in a rat focal cerebral ischemia model (Shimizu-Sasamata et aI. , 1993) . In the present study, we examined the neuroprotective ef fect of YM90K against the neuronal damage in duced by focal cerebral ischemia in anesthetized cats.
MATERIALS AND METHODS
Male ICo: Eur (Tit) cats (lFFA-CREDO, L'arbresle, France), weighing 2.7-3.5 kg, were used for study. Each cat was anesthetized with ether, tracheotomized, and connected to a ventilator delivering a mixture of nitrous oxide (70%)/oxygen (30%) (vol/vol) containing 1-1.5% halothane in a closed circuit. Femoral arteries and veins were cannulated bilaterally to monitor arterial blood pres sure and obtain arterial blood samples for blood gas de- termination, and to administer drugs and obtain blood samples for determination of plasma drug levels, respec tively. Anesthesia was maintained until the end of inves tigation. After immobilization with gallamine triethiodide (I mg/kg i.v.), normocapnia (P"co2 close to 32 mmHg) and immobilization were maintained by adjusting the stroke volume of the respirator and by administering gal lamine triethiodide (0.5 mg/kg i.v.) every 2 h, respec tively, throughout the investigation. Cats were kept warm with a heating pad and lamp; rectal temperatures were monitored. To monitor EEG, screw electrodes were im planted into the skull on the surface of the middle ecto sylvian gyri, where blood flow is mainly supplied by the middle cerebral artery (MCA). The left MCA was occluded via a modified transorbital approach (O'Brien and Waltz, 1973) . The skull was fixed in a stereotaxic frame. Using microsurgical techniques, the left orbit was exenterated and the orbital roof and optic foramen were removed using a dental drill to expose the dura overlying the MCA. Under the surgical micro scope, the dura was incised and the MeA was exposed. After dissection of the arachnoid from the MCA, the MCA trunk was occluded with a miniature clip. To stan dardize the severity of ischemia, only those cats in which mean ipsilateral EEG amplitude decreased to 30% of pre occlusion level immediately after induction of ischemia without recovery during the first 10 min of ischemia ( Fig.  1 ), were used. Under this condition, our preliminary data indicated that an occlusion time of 6 h provides maximum volume of ischemic damage. YM90K (0.25 mg/5 ml and 0.5 mg/5 ml) was dissolved in saline alkalized with a few drops of 1 N NaOH solu tion. This solution was then adjusted to pH 8-9 with I N HC!. YM90K was infused i. v., starting 10 min after the MCA occlusion, and continued for 6 h (0.25 mg/5 ml/kg/h or 0.5 mg/5 mllkg/h). Control animals were infused i.v. with saline (5 mllkg/h) prepared at pH 8-9. In all YM90K treated animals, samples of venous blood were with drawn at 2-h intervals and centrifuged, and plasma levels of the drug were determined by high-performance liquid chromatography (HPLC). In addition, in three (0.25 mg/5 mllkg/h) and four (0.5 mg/5 mllkg/h) animals, the concen tration of YM90K in cerebrospinal fluid (CSF) in the cis terna magna was determined immediately before death. Six hours after occlusion of the MeA, pentobarbital sodium (20 mg/kg) was given i. v. and the cat was killed was without reperfusion by transcardiac perfusion fixation with saline followed by 10% formalin neutral buffer solution, pH 7.4. After perfusion, the cat was de capitated and the brain removed. The brain was cut into two blocks at the coronal plane through the mammillary body. The anterior part of the brain was cut into four 4-mm thick blocks from the coronal plane. A 5-mm thick block was made by cutting the posterior part of the brain from the coronal plane. Each block was embedded in paraffin and 7-8 fLm thick sections were cut at 200-fLm intervals. Sections were stained with hematoxylin and eosin, and 12 stereotaxic coronal planes were selected according to the coordinates of Snider and Neimer (1961) . Neuronal damage was defined on the basis of the follow ing morphological characteristics: mincrovacuolation, shrinkage of the neuropil, and presence of dark neurons and eosinophilic neurons. Neuronal damage in each co ronal section was evaluated by a histologist who was blinded to animal treatment. Areas of ischemic damage in the cerebral hemisphere, cortex, and caudate were in physiological variables calculated by a computer-aided image analyzer system (Luzex III, Nireco Co., Tokyo, Japan). The volume of ischemic damage was calculated from the area of damage of the 12 coronal sections and their stereotaxic coordi nates.
In another series of experiments, a thermoprobe (29G, Physitemp Instrument Inc., Clifton, NJ U.S.A.) was in serted into the striatum (A: 18, L: 4, H: +5.5 mm) ac cording to the coordinates of Snider and Niemer (1961) to evaluate the influence of YM90K on brain temperature under similar experimental conditions. All data are presented as the means: 
RESULTS
Physiological variables, including mean arterial blood pressure (MABP) (mmHg), PaC02 (mmHg), p a02 (mmHg), pH, and rectal temperature are shown in Table I . In cats treated with YM90K (0.5 mg/5 ml/kg/h), MABP at 1 h after MCA occlusion was slightly, but significantly, decreased compared with that of saline-treated cats. Additionally, pH values of the YM90K (0.25 mg/5 ml/kg/h)-treated cats, in which no neuroprotective effect was ob served, were slightly, but significantly, decreased at 5 and 6 h after occlusion. There were no differences among the three groups for any other variables at any time. To examine whether or not the neuropro tective effect of YM90K was due to its lowering effect on the brain temperature, brain temperature was monitored under the same conditions. Brain temperature was reduced by 0.6°C at 10 min after MCA occlusion; it returned to the preocclusion level by 30 min after occlusion and gradually in creased in parallel with rectal temperature in both groups (Fig. 2 ). There were no differences in brain temperature between cats treated with YM90K (0.5 mg/5 mllkg/h), in which the volume of ischemic damage was significantly reduced, and those treated with saline ( Fig. 2) .
Effect of YM90K on neuronal damage
Administration of YM90K starting 10 min into ischemia reduced the volume of ischemic damage in the cerebral hemisphere and cortex ( compared with saline-treated cats (Table 2 ). In con trast, YM90K showed no protective effect on isch emic damage in the striatum (Table 2) Plasma levels of YM90K (0.25 and 0.5 mg/5 ml/ kg/h) continuously increased, reaching 527 ± 49 ng/ ml and 1,242 ± 146 ng/ml, respectively, at the end of experiments (Fig. 4) . CSF levels of YM90K were 7.0 ± 0.9 ng/ml (0.25 mg/5 mllkg/h) and 13.8 ± 3.0 ng/ml (0.5 mg/5 mllkg/h), indicating that CSF/ plasma ratio was � I: 100.
In preliminary studies, the effect of YM90K on the behavior of cats was observed. At 0.3-1 mg/5 ml/kg/h, YM90K showed no obvious effect on be havior, but at 3 mg/5 ml/kg/h, it induced sleep (data not shown). 
DISCUSSION
The cats used in this study are genetically more homogeneous than conventional mongrel animals. aI., 1989b). Thus, this protocol provided relatively larger and more uniform infarcts than those of other methods (Ozyurt et aI., 1988; Park et aI., 1988a; Bullock et aI., 1990) .
The present study is the first report to indicate efficacy for an AMPA/kainate antagonist when ad YM90K. This is, presumably, due to a functional recovery of cortical neurons protected by YM90K.
These results suggest that the AMPA/kainate recep tor plays an important role in the pathogenesis of focal cerebral ischemia in gyrencephalic species. A recent report using LY-293558 in the same model has also suggested this notion (Bullock et aI. , 1994) , although in that study, the compound was adminis tered in bolus 30 min before occlusion, followed by i. v. infusion during postischemic period. AMPA/ kainate antagonists, including YM90K, have been suggested to have a wide therapeutic time window (Sheardown et aI. , 1990 (Sheardown et aI. , , 1993 Li and Buchan et aI. , 1993; Shimizu-Sasamata et aI. , 1996) ; in global ce rebral ischemic models in rodents, they exert neu roprotective effects with administration even 6-24 h after insult. In transient focal ischemia in rats, NBQX and GYKI 52466 reduced neuronal damage on delayed treatment (Buchan et aI. , 1991c; Xue et aI. , 1994) . Moreover, YM90K is effective in the rat from intracellular stores (Sugiyama et aI. , 1987) , and (d) the AMPA/kainate receptor lacking the GluR2 subunit, which is also permeable to Ca 2 + (Hollmann et aI. , 1991; Verdoorn et aI., 1991) Monitoring of physiological variables, such as MABP, blood gas, and body temperature, is an es sential procedure in the evaluation of neuroprotec tive agents in cerebral ischemia models, since these parameters may affect neuronal damage . Except for a slight and transient decrease in MABP, YM90K had no effect on any physiological variables monitored. Transient hy potension may be an artifact, since it was only ob served at 1 h after the start of infusion, before the plasma level of YM90K had reached a plateau.
Since hypothermia during or after ischemia may ameliorate ischemic injury (Busto et aI. , 1989; Kuroiwa et aI. , 1990; Welsh et aI. , 1990; Xue et aI. , 1992) , both brain and rectal temperatures were monitored directly. Neither temperature was influ enced by administration of YM90K, indicating that the neuroprotective effect of YM90K is not due to decreased brain temperature.
It has been reported that quinoxalinediones, e. g., NBQX, the most extensively investigated AMPA/ kainate antagonist in cerebral ischemia (Sheardown et aI. , 1990 (Sheardown et aI. , , 1993 Buchan et aI. , 1991a , Diemer et aI., 1992 Nellgard and Wieloch, 1992; Gill et aI. , 1992) , precipitate in the renal tubules due to their low solubility (Xue et aI. , 1994) . This characteristic may limit the clinical usefulness of these com pounds. However, the present study showed that YM90K, which also has a quinoxalinedione struc ture, exerts its neuroprotective effects at a dose as low as 0.5 mg/kg/h, much lower than that at which precipitation in the kidney occurred. This dose also caused no obvious behavioral changes. In fact, al though they have similar affinities for the AMPA/ kainate receptor (Ohmori et aI. , 1994) , YM90K is more potent than NBQX in cerebral ischemia mod els (Shimizu-Sasamata et aI. , 1996) . This may be due to the higher permeability of YM90K into the brain than NBQX.
Various studies on the efficacy of glutamate an tagonists in focal cerebral ischemia models have shown that the neuroprotective effects of AMPA/ kainate antagonists, namely NBQX and LY-293558, are relatively modest as compared with those of NMDA antagonists (Ozyurt et aI., 1988; Bullock et aI. , 1990 Bullock et aI. , , 1994 Gill et al. , 199 1, 1992; Buchan et aI., 1992) . For example, L Y-293558 reduces the volume of ischemic damage in MCA-occluded cats by only �20%, while MK-80 1 reduces it by �50% in the same model (Ozyurt et aI. , 1988; Bullock et aI. , 1994) . In contrast, our present results demonstrated that YM90K reduces the volume of ischemic dam age by �40%. This suggests that the neuroprotec tive effects of AMPA/kainate antagonists are not necessarily less potent than those of NMDA antag onists. Since NMDA antagonists have the propen sity to induce such adverse effects as psychotomi metic reactions (Koek et aI. , 1988) , cognitive im pairment (Morris et aI., 1986) , and neurotoxicities (Olney et aI. , 1989, 199 1) , our present results sug gest the advantage of AMPA/kainate antagonists over NMDA antagonists in clinical usage.
In conclusion, we demonstrated that YM90K markedly reduced neuronal damage in focal cere bral ischemia in cats at a dose that is free from side effects. The efficacy of YM90K in gyrencephalic species further suggests its therapeutic potential in the treatment of stroke in humans.
